While the exact mechanism that accelerates CP efficiency is not yet established, Sipuleucel-T, the only Food and Drug Administration (FDA)-approved therapeutic cancer vaccine, provoked tumor-specific CTL responses against prostate cancer and resulted in better survival rates compared with the controls [77]. This evidence concerns the gene CP and cancer.